Tamoxifen in Men
Tamoxifen, the same SERM familiar from oncology, has two real but distinct andrological uses in men — treating and preventing gynecomastia, where the evidence is strong, and potentially supporting fertility, where the evidence is much thinner. We explain where that data actually comes from and why any direct comparison with clomiphene is, for now, only reasoned inference, not a real trial.
Number of studies
4
Safety
Requires caution
Time to effects
In gynecomastia studies, the protective effect was assessed at 6 months (Fradet et al.) and at 48 weeks (Boccardo et al.) of regular use alongside the hormonal therapy creating the risk; for hormonal-axis support, time to effect is not as well characterized in dedicated studies as it is for clomiphene.
Monthly cost
ok. 20–50 zł/miesiąc przy typowym schemacie, plus koszt wizyt i badań kontrolnych zlecanych przez lekarza
Price in Poland
ok. 20–40 zł za opakowanie (zależnie od dawki i liczby tabletek)
Who it's for
Podobnie jak przy innych SERM-ach, realny koszt terapii w praktyce zdominowany jest przez koszt diagnostyki i wizyt lekarskich, nie przez cenę samego leku.
Indicative prices for the Polish market — we don't point to specific retailers; the real price depends on the manufacturer, form and place of purchase.
Table of contents
TL;DR
Tamoxifen, the same SERM familiar from oncology, has two real but distinct andrological uses in men — treating and preventing gynecomastia, where the evidence is strong, and potentially supporting fertility, where the evidence is much thinner. We explain where that data actually comes from and why any direct comparison with clomiphene is, for now, only reasoned inference, not a real trial.
- →Strongly, in a dose-dependent way, reduces the risk of gynecomastia and breast pain linked to estrogen-androgen imbalance (data from an oncology population on bicalutamide)
- →Outperforms anastrozole (an aromatase inhibitor) head-to-head for preventing gynecomastia and breast pain in the same indication
- →Effective both prophylactically and for treating existing gynecomastia
| Active substance | Tamoxifen — selective estrogen receptor modulator (SERM) |
|---|---|
| Class | SERM, same class as clomiphene (Clostilbegyt), different usage profile |
| Approved indication | Treatment and prevention of hormone-dependent breast cancer — andrological use in men is off-label |
| Evidence level (gynecomastia) | Good — several consistent RCTs, though in an oncology population on antiandrogens, not a TRT population |
| Evidence level (fertility/testosterone) | Weak — no dedicated tamoxifen-monotherapy studies in hypogonadal men comparable to the clomiphene literature |
| Comparison with clomiphene | No head-to-head trial exists — any comparison is inference from mechanism, not clinical evidence |
| Status | Prescription only, decision and supervision by a physician (endocrinologist/andrologist/urologist; oncologist in the oncology context) |
Understand
Overview
Tamoxifen is a nonsteroidal selective estrogen receptor modulator (SERM), best known as a drug used for decades in oncology — for the treatment and prevention of hormone-dependent breast cancer in women. It belongs to the same class of compounds as clomiphene (covered in a separate entry on Clostilbegyt), but in andrological practice in men it is used in a quite different clinical context and with a different weighting of its uses.
In men, tamoxifen has two real but clearly distinct uses that are worth separating right away, since the quality of the scientific evidence behind them differs considerably. The first is treating and preventing gynecomastia — enlargement of glandular breast tissue in men, which can result from hormonal therapies (including, occasionally, TRT itself or anabolic-androgenic steroids), an imbalance between estrogen and androgens, or cancer treatment. In this use, the evidence is genuinely solid and consistent across several well-designed randomized trials. The second use is supporting fertility and endogenous testosterone production, on a principle similar to clomiphene's — but here the direct evidence is much thinner, and one of the most frequently cited studies on the topic actually involves a different, combined treatment regimen rather than tamoxifen used on its own.
The strongest data on tamoxifen's effectiveness for gynecomastia come from studies of prostate cancer patients treated with high-dose bicalutamide, an antiandrogen drug. This is an important caveat that needs to be stated every time these studies are cited: it's a completely different hormonal context from TRT. Bicalutamide blocks androgen receptors, leading to a relative predominance of estrogen action in breast tissue — the mechanism of gynecomastia there is different (though the resulting tissue effect is similar) from that in a man on TRT or steroids, where excess aromatization of testosterone to estradiol is usually the main driver. Despite this difference in context, the numbers themselves are very compelling and widely cited as the basis for using tamoxifen for this indication outside oncology as well.
In the study by Fradet and colleagues (2007), covering 282 prostate cancer patients treated with high-dose (150 mg) bicalutamide monotherapy, after 6 months breast events (gynecomastia and/or breast pain) occurred in 86.2%, 60.0%, 55.3%, 23.5%, and 8.8% of patients on tamoxifen doses of 1, 2.5, 5, 10 and 20 mg per day respectively, compared with 96.7% on placebo — a clear, strong, dose-dependent protective effect, achieved without weakening bicalutamide's PSA-suppressing effect (i.e. without compromising the effectiveness of the cancer treatment itself). In the study by Boccardo and colleagues (2005), covering 114 patients from the same population (prostate cancer on bicalutamide), after 48 weeks gynecomastia occurred in 73% of those on bicalutamide alone, 10% of those additionally receiving tamoxifen, and 51% of those additionally receiving anastrozole (an aromatase inhibitor, covered in a separate entry on this site). Breast pain: 39%, 6%, and 27% respectively. Tamoxifen clearly outperformed anastrozole for this specific indication — a useful, real data point for readers comparing these two drug classes specifically for gynecomastia, though it shouldn't be taken to mean tamoxifen is generally 'better' than aromatase inhibitors in every other clinical context. A third study (Saltzstein et al., 2005), covering 107 patients of the same type, confirmed the same pattern — tamoxifen, unlike anastrozole, significantly reduced the incidence of gynecomastia and breast pain in both the prophylactic (preventive) and therapeutic (treating existing gynecomastia) settings; in this study, testosterone also rose with tamoxifen relative to placebo.
When it comes to the second use — supporting fertility and endogenous hormone production — the evidence is noticeably weaker than for clomiphene. A frequently cited study by Adamopoulos and colleagues (2003) found a spontaneous pregnancy rate of 33.9% in the treated group versus 10.3% in the placebo group — a result that looks very promising at first glance. An important caveat needs to be introduced here, though: in that study, tamoxifen was used in combination with exogenous testosterone undecanoate, not as SERM monotherapy. That's a materially different treatment regimen from 'tamoxifen alone preserving fertility the way clomiphene does' — the exogenous testosterone component in that trial would itself suppress the HPG axis, so the study doesn't cleanly demonstrate tamoxifen as a standalone fertility-preserving therapy in the way the clomiphene studies do for that drug, described in the entry on Clostilbegyt.
It's also worth stating plainly something rarely mentioned in popular sources: a direct search for studies comparing tamoxifen with clomiphene in men returns no results in the PubMed database. In other words, there is no head-to-head clinical trial directly comparing these two drugs in men with hypogonadism or fertility issues. Any claim that one of these drugs is 'better' than the other at raising endogenous testosterone is an extrapolation from separate studies and reasoning from mechanism, not the result of an actual comparative trial — a distinction worth keeping in mind for anyone who comes across forum or social media discussions comparing these two substances as though hard, conclusive data existed.
To sum up the practical picture: tamoxifen has solid, repeatable evidence for treating and preventing gynecomastia, though that evidence comes from an oncology population using antiandrogens rather than directly from men on TRT. Its use as an alternative to clomiphene for preserving fertility has much thinner direct scientific support and relies more on analogy from mechanism of action (both are SERMs) than on dedicated clinical trials in this specific population.
Mechanism of action
Tamoxifen, like clomiphene, is a nonsteroidal SERM with tissue-dependent activity — in some tissues it behaves as an estrogen receptor antagonist, in others as a partial agonist. This tissue-specific nature explains why it can simultaneously protect against gynecomastia (acting as an antagonist on estrogen receptors in glandular breast tissue, blocking estrogen's proliferative effect on that tissue) and potentially affect the HPG axis in a way similar to clomiphene (acting as an antagonist on estrogen receptors in the hypothalamus, weakening the negative feedback normally exerted by estrogen and thereby increasing GnRH, LH and FSH release).
In the context of gynecomastia, the mechanism is relatively well understood: breast tissue in men, as in women, carries estrogen receptors, and proliferation of that tissue (i.e. gynecomastia itself) is driven mainly by estrogen action that isn't balanced by adequate androgen action. By blocking these receptors directly in breast tissue, tamoxifen limits circulating estrogen's ability to stimulate its growth — regardless of whether the excess estrogen results from testosterone aromatization (as with TRT or anabolic-androgenic steroids) or from a hormonal imbalance induced by antiandrogen drugs (as in the cited oncology studies on bicalutamide).
In the context of the HPG axis, the mechanism is analogous to clomiphene, described more fully in the entry on Clostilbegyt: blocking estrogen receptors in the hypothalamus weakens estrogen's normal inhibitory effect on GnRH release, leading to increased LH and FSH secretion from the pituitary and, in turn, increased endogenous testosterone production by the Leydig cells in the testes, without suppressing the body's own hormonal axis the way TRT does. It should be stressed, though, that while this mechanism is well documented for clomiphene across numerous studies dedicated to men with hypogonadism, for tamoxifen there are far fewer direct studies confirming the same clinical effect in men with infertility or hypogonadism when used as monotherapy.
Tissue-specific activity
As a SERM, tamoxifen acts as an estrogen receptor antagonist in some tissues (breast, hypothalamus) and as a partial agonist in others — hence its varied clinical uses.
Blocking estrogen receptors in breast tissue
In glandular breast tissue, tamoxifen blocks estrogen's ability to stimulate proliferation, limiting the development and severity of gynecomastia.
Blocking estrogen receptors in the hypothalamus
Analogous to clomiphene, blocking these receptors weakens estrogen's inhibitory feedback, increasing GnRH release.
Rise in LH, FSH and endogenous testosterone
Increased GnRH raises LH and FSH from the pituitary, stimulating the Leydig cells to increase their own testosterone production — a mechanism confirmed mainly for clomiphene, and studied less directly for tamoxifen.
Evidence: moderate — based on 4 studies in this database.
Benefits
Common myths
MythTamoxifen and clomiphene work identically, so they can be used interchangeably without any difference.
FactBoth drugs belong to the same SERM class, but they have different evidence profiles: tamoxifen has stronger data for treating gynecomastia, clomiphene has stronger, dedicated data for hypogonadism and fertility in men. No head-to-head trial exists comparing them directly, so claiming they're equivalent is inference, not evidence.
MythSince the tamoxifen studies on gynecomastia show such good results, they also prove effectiveness in men on TRT.
FactThe strongest tamoxifen studies on gynecomastia come from a population of prostate cancer patients treated with high-dose bicalutamide, an antiandrogen drug — not from men on TRT. That's a different hormonal context, though the results are often extrapolated to other clinical situations due to the lack of dedicated studies in a TRT population.
MythThe Adamopoulos et al. (2003) study proves that tamoxifen alone effectively preserves fertility, just like clomiphene.
FactIn that study, tamoxifen was used together with exogenous testosterone undecanoate, not as a standalone SERM therapy — a materially different regimen that doesn't cleanly demonstrate tamoxifen as a fertility-preserving monotherapy.
Forms & variants
Tamoxifen in Men comes in several forms that differ in bioavailability and use case — the form you pick genuinely matters for how effective the supplementation is.
Tamoxifen (international name)
The active substance is available under various brand names depending on manufacturer and market, always by prescription.
Best for: Patients under a physician's care — the specific product chosen depends on availability and the physician's recommendation
Practice
Frequently asked questions
It has two main andrological uses: treating and preventing gynecomastia (breast tissue enlargement), where the evidence is solid, and potentially supporting endogenous testosterone production on a principle similar to clomiphene, where direct evidence in hypogonadal men is much thinner.
There's no evidence-based answer to this — no clinical trial directly compares the two drugs in men. Tamoxifen has stronger data for treating gynecomastia; clomiphene has stronger, dedicated data for hypogonadism. The choice between them should be made by the treating physician based on the individual clinical picture, not on comparisons based purely on mechanism of action.
Not directly. The strongest studies (Fradet et al. 2007, Boccardo et al. 2005, Saltzstein et al. 2005) involve prostate cancer patients treated with high-dose bicalutamide, an antiandrogen drug. That's a different hormonal context from TRT, though the results are sometimes treated as supporting tamoxifen's use in other gynecomastia-related situations, with that population caveat noted.
The evidence for this is considerably weaker than for clomiphene. The frequently cited Adamopoulos et al. (2003) study showed a high pregnancy rate, but it used tamoxifen together with exogenous testosterone, not as a standalone therapy — which makes it incomparable to studies on clomiphene used alone to preserve fertility.
No, it's a prescription-only medication. The decision to use it in a man, regardless of indication (gynecomastia or hormonal support), should always follow consultation with a physician — typically an endocrinologist, urologist/andrologist, or, in the oncology context, an oncologist.
Head-to-head with anastrozole (an aromatase inhibitor) in the same indication, tamoxifen performed noticeably better — in one study, gynecomastia occurred in 10% of patients on tamoxifen versus 51% on anastrozole, on the same background therapy. That's data from a specific oncology context, though, not a universal statement about tamoxifen's superiority across all uses.
Dosage & timing
Typical dose
Studies on gynecomastia used doses from 1 mg to 20 mg per day, with a clear dose-dependent protective effect — a specific regimen for a man outside the oncology context is set individually by the treating physician
Form
Oral tablets
Dosing information reflects the ranges used in the cited studies and does not replace consulting a doctor or pharmacist. Tamoxifen dosing in men, whether for gynecomastia or potential hormonal support, is set exclusively by the treating physician based on a full diagnostic workup — this is not a drug to self-dose based on regimens found online.
Best times to take it
- Consistency of use matters more than a specific time of day — this is determined by the physician's chosen schedule
- For prophylactic use (preventing gynecomastia), treatment is usually started alongside the hormonal therapy that creates the risk
- The hormonal and clinical effect is assessed by the physician based on regular follow-up tests during treatment
What to combine with
Use caution with
TRT (Testosterone Replacement Therapy) — What Is It and Who Is It For? — In the context of supporting endogenous hormone production, combining with exogenous testosterone defeats the purpose of that use
Safety
Side effects & contraindications
Possible side effects
Possible gastrointestinal discomfort
Hot flashes reported by some patients, similar to other estrogen-modulating therapies
Rarely: mood changes
Theoretical thromboembolic risk, known from long-term oncology use in women — in the shorter andrological regimens in men, this risk isn't as well quantified in the cited literature
As with any hormonally active drug — possible individual reactions requiring observation by the treating physician
Contraindications
History of thromboembolic disease or active clotting risk — requires individual assessment by a physician
Liver disease — the drug is hepatically metabolized
Hypersensitivity to the active substance
Use without prior diagnosis of the underlying cause of gynecomastia or hormonal imbalance — the underlying cause should always be established rather than just treating the symptom
Interactions
Exogenous testosterone (TRT) — in the context of supporting endogenous hormone production, combining with external testosterone defeats the purpose of that use, similar to clomiphene
Aromatase inhibitors (e.g. anastrozole) — in the cited comparative studies, tamoxifen, not anastrozole, was more effective at preventing gynecomastia in this specific indication; combining both requires specialized endocrinological expertise
Drugs affecting blood clotting — requires attention from the treating physician given the thromboembolic risk described in the oncology literature
Is it worth taking?
Who it's for
- Men with gynecomastia related to hormonal therapy (including, occasionally, TRT) or an estrogen-androgen imbalance, under a physician's care
- Oncology patients on antiandrogen hormonal therapy, for whom gynecomastia prophylaxis is part of standard care (an oncologist's decision)
- Possibly, in individually assessed cases, men considering support for endogenous testosterone production — but with full awareness that the evidence for this use is thinner than for clomiphene
- Definitely NOT as a self-selected drug based on online comparisons with clomiphene — such a comparison has no basis in any head-to-head trial
Not for
- History of thromboembolic disease or active clotting risk — requires individual assessment by a physician
- Liver disease — the drug is hepatically metabolized
- Hypersensitivity to the active substance
- Use without prior diagnosis of the underlying cause of gynecomastia or hormonal imbalance — the underlying cause should always be established rather than just treating the symptom
Evidence
Worth knowing
Tamoxifen and clomiphene (Clostilbegyt) belong to the same drug class — SERMs — but have different primary clinical uses in men.
The strongest evidence for tamoxifen's effectiveness in gynecomastia comes from studies of oncology patients on bicalutamide, not a TRT population.
Head-to-head, tamoxifen was more effective at preventing gynecomastia than anastrozole (an aromatase inhibitor) in the same indication.
No published study directly compares tamoxifen with clomiphene in men — searching for such a study on PubMed returns no results.
Studies
Breast events occurred in 86.2% down to 8.8% of patients (depending on tamoxifen dose, 1-20 mg) versus 96.7% on placebo — a clear, dose-dependent protective effect, without weakening the effectiveness of the underlying cancer therapy.
Fradet Y et al., European Urology, 2007
Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study
Moderate evidenceFradet Y, Egerdie B, Andersen M, et al. · European Urology · 2007
In 282 prostate cancer patients on high-dose bicalutamide, at 6 months breast events occurred in 86.2% down to 8.8% of patients (depending on tamoxifen dose, 1-20 mg) versus 96.7% on placebo — a clear, dose-dependent protective effect, without weakening bicalutamide's PSA suppression.
View studyEvaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer
Moderate evidenceBoccardo F, Rubagotti A, Battaglia M, et al. · Journal of Clinical Oncology · 2005
In 114 patients from the same population, at 48 weeks gynecomastia occurred in 73% (bicalutamide alone) versus 10% (+tamoxifen) and 51% (+anastrozole); breast pain: 39% versus 6% and 27%. Tamoxifen clearly outperformed anastrozole for this indication.
View studyPrevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole
Moderate evidenceSaltzstein D, Sieber P, Morris T, Gallo J · Prostate Cancer and Prostatic Diseases · 2005
In 107 patients from the same population, tamoxifen (not anastrozole) significantly reduced the incidence of gynecomastia and breast pain both prophylactically and therapeutically; testosterone also rose with tamoxifen relative to placebo.
View studyEffectiveness of combined tamoxifen citrate and testosterone undecanoate treatment in men with idiopathic oligozoospermia
Early-stage evidenceAdamopoulos DA, Pappa A, Billa E, Nicopoulou S, Koukkou E, Michopoulos J · Fertility and Sterility · 2003
Spontaneous pregnancy rate was 33.9% (treated) versus 10.3% (placebo), but the regimen combined tamoxifen with exogenous testosterone undecanoate rather than testing tamoxifen as monotherapy — a materially different regimen than SERM-monotherapy fertility preservation in the sense used for clomiphene studies.
View studySources & bibliography
Citations are illustrative for this demo version and require full bibliographic verification by the editorial team before production publication.
Compare with similar entries
About the authors of this entry
Author
dr Piotr ZielińskiEndocrinologist
Piotr reviews content on hormones, metabolic health and supplement pharmacology.
131 publications on this site
Medical review
dr Anna KowalczykEditor-in-Chief, Molecular Biology
Anna oversees the editorial process and scientific review of every publication in the knowledge base. She previously researched autophagy and mitochondrial biology.
50 publications on this site
Related entries
4.5Clomiphene in Men
Clomiphene citrate — known in Poland under the brand name Clostilbegyt — raises testosterone through a completely different route than TRT: instead of supplying the hormone from outside, it tricks the brain into making the testes produce more of their own. That makes it attractive to men who care about fertility, but the popular claim that it's simply a 'fertility drug' needs to be checked against the actual data.
4.6TRT and Estradiol — Why Does Estrogen Rise During Testosterone Therapy?
Many men on TRT watch their estradiol climb on their blood work with alarm. We explain the mechanism of aromatization, which symptoms are genuinely caused by excess estrogen and which are wrongly blamed on it — and why routinely blocking aromatase with an inhibitor is often a mistake.
4.4hCG as Adjunct Therapy in TRT
Human chorionic gonadotropin is sometimes added to testosterone replacement therapy specifically to prevent testicular atrophy and preserve fertility — a problem exogenous testosterone alone doesn't solve.
4.7TRT — Side Effects and Therapy Monitoring
Erythrocytosis, fertility impact, PSA screening, and the cardiovascular risk question — what testosterone replacement therapy safety actually involves and how it's monitored.
4.7TRT (Testosterone Replacement Therapy) — What Is It and Who Is It For?
TRT isn't a supplement for fatigue — it's pharmacological treatment for a confirmed testosterone deficiency, with a real but limited list of benefits and an equally real list of people who simply don't qualify for it.
4.7What Tests Are Needed Before TRT? The Complete Pre-Treatment Testing List
Before a physician can qualify a patient for testosterone therapy, a far broader panel of tests is needed than testosterone level alone. The full list of blood tests, symptom questionnaires, and criteria that determine whether TRT is safe and appropriate.
4.7How Often to Test Testosterone on TRT? Monitoring Schedule and Checkups
Starting testosterone therapy isn't the end of diagnostics — it's the start of a new, recurring rhythm of checkups. We explain which tests happen at month 3, which at year one, and which need repeating for as long as therapy continues — and how the schedule differs between injectable and gel forms.
Related articles
PoradnikiTRT and Fertility: Can Testosterone Therapy Cause Infertility?
Testosterone replacement therapy can suppress sperm production even in men with a 'perfect' blood testosterone result — we explain the mechanism, the real scale of the problem, and the concrete options for men who want to have children.
August 15, 2026
PoradnikiDoes TRT Cause Hair Loss, Acne, and Gynecomastia? Fact vs. Myth
Hair loss, acne, and 'man boobs' are the three most-Googled worries before starting TRT — but none of them is a guaranteed consequence of therapy. We check what physiology and the research actually say about mechanism, dose, and individual susceptibility.
August 15, 2026
PoradnikihCG During TRT — When Is It Used, and Does It Help Preserve Fertility?
hCG gets added to testosterone therapy precisely so you don't lose fertility while on treatment — we explain what that looks like in practice: typical dosing, real-world effectiveness, and who it's actually a sensible option for, and who it isn't enough for.
August 15, 2026
PoradnikiClomid or TRT — What to Choose for Low Testosterone?
Clomiphene and TRT raise testosterone through completely different routes — one stimulates the body to produce its own hormone, the other replaces it from outside. We explain why that difference matters critically for some men, especially around fertility.
August 15, 2026
Comments (2)
- KW
Kasia W. 2 weeks ago
Very clearly explained, especially the interactions section — I hadn't seen it laid out this well anywhere else.
- MT
Marek T. a month ago
Are you planning to update this with the newest study from this year? I saw an interesting meta-analysis.